

Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux coagulation POC and platelet function tests

Clinical Chemistry and Laboratory Medicine

52, 835-44

DOI: [10.1515/cclm-2013-0936](https://doi.org/10.1515/cclm-2013-0936)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 479-501.	0.7	29
2	A critical appraisal of point-of-care coagulation testing in critically ill patients. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1960-1967.	1.9	65
3	Usefulness of Platelet Function Tests to Predict Bleeding With Antithrombotic Medications. <i>Cardiology in Review</i> , 2015, 23, 323-327.	0.6	5
4	Viscoelastic Methods of Blood Clotting Assessment – A Multidisciplinary Review. <i>Frontiers in Medicine</i> , 2015, 2, 62.	1.2	43
5	UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. <i>PLoS ONE</i> , 2015, 10, e0145478.	1.1	35
6	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.7	3
7	Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection. <i>Chinese Journal of Traumatology - English Edition</i> , 2015, 18, 147-149.	0.7	3
8	Impact of dabigatran on platelet function and fibrinolysis. <i>Journal of the Neurological Sciences</i> , 2015, 357, 204-208.	0.3	10
9	Laboratory Testing in the Era of Direct or Non-Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 208-227.	1.5	95
10	Global assays and the management of oral anticoagulation. <i>Thrombosis Journal</i> , 2015, 13, 9.	0.9	48
11	Assessing the influence of diurnal variations and selective Xa inhibition on whole blood aggregometry. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 531-536.	0.6	4
12	Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants. <i>Stroke</i> , 2015, 46, 2741-2747.	1.0	62
13	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 115, 622-631.	1.8	23
15	Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation. <i>Medicine (United States)</i> , 2016, 95, e3037.	0.4	18
16	Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. <i>Science Translational Medicine</i> , 2016, 8, 367ra168.	5.8	32
17	Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. <i>Platelets</i> , 2016, 27, 687-693.	1.1	16
18	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. <i>Critical Care</i> , 2016, 20, 273.	2.5	19
19	Whole Blood Assay: Thromboelastometry. , 2016, , 37-64.		7

#	ARTICLE	IF	CITATIONS
20	Periprocedural Management of Novel Oral Anticoagulants During Atrial Fibrillation Ablation: Controversies and Review of the Current Evidence. <i>Heart Lung and Circulation</i> , 2016, 25, 1164-1176.	0.2	8
21	TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. <i>Thrombosis Research</i> , 2016, 138, 63-68.	0.8	31
22	Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 161-166.	1.0	21
23	Assessment of the Effects of Antithrombotic Drugs. , 2016, , 173-192.		0
25	Rotational thromboelastometry in ex vivo samples from routine clinical practice patients receiving dabigatran. <i>Clinica Chimica Acta</i> , 2017, 466, 20-21.	0.5	3
26	Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1522-1523.	1.9	1
27	Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 216-222.	1.0	23
28	Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment. <i>Thrombosis Research</i> , 2017, 153, 76-82.	0.8	28
29	Impact of rivaroxaban on point-of-care assays. <i>Thrombosis Research</i> , 2017, 153, 65-70.	0.8	26
30	Point-of-Care Coagulation Tests Monitoring of Direct Oral Anticoagulants and Their Reversal Therapy: State of the Art. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 423-432.	1.5	22
31	The use of frozen plasma samples in thromboelastometry. <i>Clinical and Experimental Medicine</i> , 2017, 17, 489-497.	1.9	12
32	Direct oral anticoagulants and heparins: laboratory values and pitfalls in "bridging therapy". <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 51, ezw368.	0.6	7
33	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	1.2	285
34	Impact of the Direct Oral Anticoagulants on Activated Clotting Time. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, e24-e27.	0.6	15
35	Practical Use of Thromboelastometry in the Management of Perioperative Coagulopathy and Bleeding. <i>Transfusion Medicine Reviews</i> , 2017, 31, 11-25.	0.9	36
36	Optimal Reversal of Novel Anticoagulants in Trauma. <i>Critical Care Clinics</i> , 2017, 33, 135-152.	1.0	10
37	Measurement and reversal of the direct oral anticoagulants. <i>Blood Reviews</i> , 2017, 31, 77-84.	2.8	133
38	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. <i>Chest</i> , 2017, 151, 127-138.	0.4	245

#	ARTICLE	IF	CITATIONS
39	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 457-467.	1.0	40
40	Optical sensing of anticoagulation status: Towards point-of-care coagulation testing. <i>PLoS ONE</i> , 2017, 12, e0182491.	1.1	20
41	Viscoelastic testing inside and beyond the operating room. <i>Journal of Thoracic Disease</i> , 2017, 9, S299-S308.	0.6	50
42	Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants. <i>Thrombosis Research</i> , 2018, 165, 101-106.	0.8	23
43	Outcomes of Early Surgical Intervention in Geriatric Proximal Femur Fractures Among Patients Receiving Direct Oral Anticoagulation. <i>Journal of Orthopaedic Trauma</i> , 2018, 32, 269-273.	0.7	36
44	Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). <i>Thrombosis Research</i> , 2018, 163, 100-104.	0.8	11
45	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>British Journal of Anaesthesia</i> , 2018, 120, 645-656.	1.5	115
46	Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry – a prospectively controlled randomized double-blind clinical trial. <i>BMC Anesthesiology</i> , 2018, 18, 18.	0.7	25
49	Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM). <i>International Journal of Laboratory Hematology</i> , 2018, 40, 84-93.	0.7	59
50	Secondary Gains. <i>Emergency Medicine Clinics of North America</i> , 2018, 36, 107-133.	0.5	15
51	Con: Activated Clotting Time Should Not Be Monitored During Heparinization for Vascular Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1497-1499.	0.6	2
52	Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin-based trigger. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2462-2470.	1.9	13
53	Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 194S-201S.	0.7	8
54	Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1775-1778.	1.1	5
55	Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays. <i>Clinica Chimica Acta</i> , 2018, 486, 347-356.	0.5	27
56	Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1199-1207.	0.7	28
57	Rivaroxaban May Increase Platelet Activation In Vivo via Thromboxane A2. <i>Circulation Research</i> , 2019, 125, e9.	2.0	5
58	Head Trauma. , 2019, , 87-104.		0

#	ARTICLE	IF	CITATIONS
59	Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration – results from a diabetes animal model. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 538-550.	1.9	8
60	Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984752.	0.7	19
61	The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIIb/IIIa-Mediated Platelet Aggregation. <i>Thrombosis and Haemostasis</i> , 2019, 119, 916-929.	1.8	14
62	Pharmacological strategies for targeting platelet activation in asthma. <i>Current Opinion in Pharmacology</i> , 2019, 46, 55-64.	1.7	22
63	Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood. <i>European Journal of Anaesthesiology</i> , 2019, 36, 449-456.	0.7	22
64	Advances in monitoring anticoagulant therapy. <i>Advances in Clinical Chemistry</i> , 2019, 90, 197-213.	1.8	9
65	Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 272-279.	1.0	10
66	The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis. <i>Platelets</i> , 2020, 31, 43-47.	1.1	3
67	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	1.2	187
68	Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs. <i>Journal of Arrhythmia</i> , 2020, 36, 644-651.	0.5	2
69	Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. <i>Leukemia and Lymphoma</i> , 2020, 61, 3422-3431.	0.6	1
70	Point-of-Care Hematology. , 2020, , 123-138.		0
71	Assessing the hemostasis with thromboelastometry in direct oral anticoagulants-treated patients with atrial fibrillation. <i>Thrombosis Research</i> , 2020, 191, 38-41.	0.8	2
72	Reduction of Preoperative Waiting Time Before Urgent Surgery for Patients on P2Y12 Inhibitors Using Multiple Electrode Aggregometry: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 424.	1.0	4
73	Reversing the Effect of Anticoagulants Safety in Patients Undergoing Emergency Surgery. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2021, , 79-95.	0.1	0
74	ROTEM Testing for Direct Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 815-823.	1.5	9
75	Impact of Dabigatran Treatment on Rotation Thromboelastometry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962098390.	0.7	8
76	Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran. <i>Thrombosis and Haemostasis</i> , 2021, 121, 782-791.	1.8	5

#	ARTICLE	IF	CITATIONS
77	Thermally driven formation of polyphenolic carbonized nanogels with high anticoagulant activity from polysaccharides. <i>Biomaterials Science</i> , 2021, 9, 4679-4690.	2.6	9
78	Rotational Thromboelastometry (ROTEM®). , 2016, , 267-298.		28
79	Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase. <i>PLoS ONE</i> , 2016, 11, e0149077.	1.1	4
80	Klinisch-chemische Diagnostik in der Anästhesiologie. , 2016, , 1-30.		0
81	Klinisch-chemische Diagnostik in der Anästhesiologie. Springer Reference Medizin, 2019, , 591-619.	0.0	0
82	Rotational Thromboelastometry (ROTEM®). , 2021, , 279-312.		3
83	Reversal of anticoagulation in neurosurgical and neurocritical care settings. , 2022, , 239-266.		0
84	Pre- and Perioperative Management of Hip Fracture. , 2022, , 483-494.		0
85	Less than No Time Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1407.	1.0	14
86	Biological Variation in Rotational Thromboelastometry in Patients with Atrial Fibrillation Receiving Rivaroxaban. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 205.	0.8	1
87	Towards 50 years of platelet function analyser (PFA) testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 851-860.	1.4	10
88	Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop. <i>TH Open</i> , 2022, 06, e238-e247.	0.7	2
89	The potential role of ischaemia reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. <i>Biochemical Journal</i> , 2022, 479, 1653-1708.	1.7	27
90	Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function. <i>Toxicologic Pathology</i> , 0, , 019262332211292.	0.9	0
91	Recent advances in laboratory hematology reflected by a decade of <i>CCLM</i> publications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, ,	1.4	1
92	Platelets and Their Role in Hemostasis and Thrombosis From Physiology to Pathophysiology and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12772.	1.8	16
93	The impact of direct oral anticoagulants on viscoelastic testing A systematic review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8
94	The protective effect of rivaroxaban with or without aspirin on inflammation, oxidative stress, and platelet reactivity in isoproterenol-induced cardiac injury in rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2023, 396, 337-351.	1.4	2

#	ARTICLE	IF	CITATIONS
95	Impact of surface coating and systemic anticoagulants on hemostasis and inflammation in a human whole blood model. PLoS ONE, 2023, 18, e0280069.	1.1	1
96	Smoking and Activated Clotting Time during coronary angiography and angioplasty: protocol for the ACT-Tobacco trial. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100083.	1.0	1
97	Comparative Analysis of Roots from <i>Vicatia thibetica</i> de Boiss and <i>Angelica sinensis</i> Based on Chemical Composition, Antioxidant, Nitrite-Scavenging and Enzyme Inhibition Activities. Molecules, 2023, 28, 1942.	1.7	1
98	Immature platelets in COVID-19. Platelets, 2023, 34, .	1.1	4
99	Pharmacological methods for blood stabilization in the extracorporeal circuit (review of literature). Messenger of Anesthesiology and Resuscitation, 2023, 20, 81-88.	0.1	0